Advertisement

Topics

INTRON BIO TECHNOLOGY Company Profile

02:23 EST 12th December 2018 | BioPortfolio

NIL

Location

Sangdaewon-Dong, Joongwon-Ku
Sungnam
Kyungki-Do
462-120
South Korea

Contact

Phone: 82-505-550-5600
Fax: 82-505-550-5660
Email: intron@intron.co.kr


News Articles [132 Associated News Articles listed on BioPortfolio]

Roivant and iNtRON sign licensing deal for SAL200

Roivant Sciences and iNtRON Biotechnology have signed a $667.5m global licensing agreement for SAL200, which is an investigational biologic to...Read More... The post Roivant and iNtRON sign licensing...

Roivant Licenses iNtRON Bio's Anti-Bacterial in $667.5 Million Deal

Under the terms of the deal, Roivant is paying iNtRON Bio $10 million upfront. iNtRON will be eligible for milestone payments. When the first patient receives treatment in a U.S. Phase II clinical tri...

Deals this week: Roivant Sciences, Inflazome, Santhera

Roivant Sciences will use biologic drug candidate SAL200 are entering a global licensing agreement worth $667.5m with iNtRON Biotechnology. iNtRON...Read More... The post Deals this week: Roivant Scie...

Roivant gets rights to iNtRON's SAL200

Roivant Sciences GMBH licensed worldwide rights to iNtRON Biotechnology Inc.’s infectious disease compound SAL200.

Roivant, iNtRON Bio ink licensing deal for novel anti─superbugs biologic SAL200

Roivant Sciences and iNtRON Biotechnology have entered into a global licensing agreement for SAL200, a novel investigational biologic for the treatment of infectious diseases caused by antibiotic─re...

Roivant Buoys Anti-Infective Portfolio With Novel iNtRON Asset

Roivant Sciences has added iNtRON Biotechnology’s novel biologic candidate to its existing anti-infective portfolio in a sizable licensing deal amid...   

Intron retention is a source of neoepitopes in cancer

Roivant gets rights to iNtRON's endolysin-based antibiotic

Drugs and Medications [194 Associated Drugs and Medications listed on BioPortfolio]

Ribavirin [Aurobindo Pharma Limited]

These highlights do not include all the information needed to use ribavirin safely and effectively. See full prescribing information for ribavirin capsules. Ribavirin Capsules Initial U.S. Approval: ...

Ribavirin [Zydus Pharmaceuticals (USA) Inc.]

These highlights do not include all the information needed to use ribavirin capsules safely and effectively. See full prescribing information for ribavirin capsules. Initial U.S. Approval: 1998

Ribavirin [Cadila Healthcare Limited]

These highlights do not include all the information needed to use ribavirin capsules safely and effectively. See full prescribing information for ribavirin capsules. Initial U.S. Approval: 1998

Ribavirin [Sandoz Inc]

These highlights do not include all the information needed to use Ribavirin safely and effectively. See full prescribing information for Ribavirin.Ribavirin Capsules Initial U.S. Approval: 1998

Ribavirin [American Health Packaging]

These highlights do not include all the information needed to use Ribavirin safely and effectively. See full prescribing information for Ribavirin.Ribavirin Capsules Initial U.S. Approval: 1998

PubMed Articles [614 Associated PubMed Articles listed on BioPortfolio]

Identification of a variant-associated with early-onset diabetes in the intron of INS gene with exome sequencing.

Whole-exome sequencing is a new technology. We used it to explore the gene responsible for early-onset diabetes due to impaired insulin secretion in a family. In the INS gene, we identified the hetero...

A super-enhancer maintains homeostatic expression of Regnase-1.

Regnase-1 is not only a key component in maintaining intracellular homeostasis but also a critical negative regulator in preventing autoimmune diseases and cancer development. To keep homeostatic stat...

Intron retention is a source of neoepitopes in cancer.

We present an in silico approach to identifying neoepitopes derived from intron retention events in tumor transcriptomes. Using mass spectrometry immunopeptidome analysis, we show that retained intron...

Structural accommodations accompanying splicing of a group II intron RNP.

Group II introns, the putative progenitors of spliceosomal introns and retrotransposons, are ribozymes that are capable of self-splicing and DNA invasion. In the cell, group II introns form ribonucleo...

Genome-wide identification, phylogenetic classification, and exon-intron structure characterisation of the tubulin and actin genes in flax (Linum usitatissimum).

Flax (Linum usitatissimum L.) is a valuable food and fiber crop cultivated for its quality fiber and seed oil. α-, β-, γ-tubulins and actins are the main structural proteins of the cytoskeleton. α...

Clinical Trials [1539 Associated Clinical Trials listed on BioPortfolio]

SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron) vs. INTRON®A as Adjuvant Therapy for Melanoma (MK-4031-002)

This is a Phase II/III randomized, controlled, multicenter, open-label study designed to assess the safety, efficacy, and impact on quality of life of PEG Intron and INTRON® A and the pop...

Phase III PEG-Intron in HIV-infected Patients (Study P00738)

This is a randomized, double-blind, multicenter trial testing 2 doses of PEG-Intron, 1.0mcg/kg/week and 3.0mcg/kg/week in heavily treatment-experienced HIV-infected patients compared to pl...

Safety, Tolerability, and Anti-HIV Activity of PEG-Intron in HIV-Positive Children

The purpose of this study is to see if PEG-Intron is safe and tolerated when given to children, to see how much gets into the blood and how long it stays in the blood, and to see how well ...

Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron

This is an open-label, single-arm, multicenter Phase II safety and efficacy study of combination therapy with pembrolizumab and PEG-Intron (Peginterferon alpha-2b) in patients with advance...

Peg-Intron Versus Adefovir in the Treatment of Chronic Hepatitis B (CHB) e Antigen Positive Patients in Taiwan (Study P04498)(COMPLETED)

This is an open label, randomized, comparative, multi-center study. Subjects will be screened within 2 weeks prior to study entry to establish eligibility. Subjects who meet all the sele...

Companies [445 Associated Companies listed on BioPortfolio]

INTRON BIO TECHNOLOGY

NIL

Exon-Intron, Inc.

Exon-Intron, Inc. is a biotechnology education firm. This year we celebrate our 18th anniversary and the continuation of our long tradition as a provider of expert technical training to scientists of ...

Receptor BioLogix

Receptor BioLogix, Inc. is a biopharmaceutical company focused on developing the first broad-spectrum anti-HER therapeutic, resulting from its program to commercialize a newly discovered class of prot...

Receptor BioLogix, Inc.

Receptor BioLogix, Inc. is a biopharmaceutical company focused on developing the first broad-spectrum anti-HER therapeutic, resulting from its program to commercialize a newly discovered class of prot...

Enzon Pharmaceuticals

We are a biopharmaceutical company dedicated to the development and commercialization of therapeutics to treat patients with cancer and other life-threatening diseases. Our specialized sales force mar...

More Information about "INTRON BIO TECHNOLOGY" on BioPortfolio

We have published hundreds of INTRON BIO TECHNOLOGY news stories on BioPortfolio along with dozens of INTRON BIO TECHNOLOGY Clinical Trials and PubMed Articles about INTRON BIO TECHNOLOGY for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of INTRON BIO TECHNOLOGY Companies in our database. You can also find out about relevant INTRON BIO TECHNOLOGY Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record